Research on the biology of tumor cells. Covers tumor spread, cell-particle diagnostics, new anti-tumor molecules, and cancer-killing immune cells.
A study found that pancreatic cancer cells can behave differently based on their surroundings, with some responding better to chemotherapy and radiation. The stroma of tumors consists of connective tissue cells that contribute to tumor growth and spread.
A molecule called LL-37 has been found to boost the function of dendritic cells, which are used in cancer therapy. This improvement could lead to more effective treatments by increasing the success rate of dendritic cell-based therapies.
A human enzyme named FANCM is essential for the survival of cancer cells using an alternative telomere lengthening pathway. ALT tumor cells require FANCM activity to prevent telomere instability and cell death.
Researchers at VCU Massey Cancer Center have made a significant discovery regarding tumor dormancy, a state of inactivity that allows cancer cells to evade detection and recurrence. By targeting senescent cells, they hope to develop novel therapeutics that can eliminate dormant tumor cells and prevent disease recurrence.
Research at Technical University of Munich shows that molecular chaperones Hsp70 and Hsp40, as well as Hsp90, control the function of p53 by influencing its three-dimensional structure. This helps prevent cancer cells from growing.
Researchers have developed a new technique called BiGluc, which enables the visualization of glucose metabolism in real-time in cancerous tumors. This non-invasive imaging method could lead to more effective cancer treatments by identifying the metabolic requirements of different tumors.
Researchers at University of Helsinki found that MDGI protein plays a key role in regulating lysosomal membrane stability. Inhibiting this protein causes glioblastoma cell death, particularly with antihistamine clemastine, which can cross the blood-brain barrier.
Researchers have engineered molecules that restrict access to heme, an oxygen-binding molecule, to slow the growth of lung cancer tumors in mice. By starving cancer cells of this essential molecule, the new approach may provide a potential new path forward in treating non-small cell lung cancer.
Researchers found that the interaction between pancreatic stellate cells and cancer cells could be exploited due to high levels of LIF, a key protein responsible for activating PSCs in cancer cells. Elevated LIF levels correlate with disease progression and chemotherapy resistance.
Researchers at Salk Institute uncover role of signaling protein LIF in pancreatic cancer development and progression, suggesting it may be a useful biomarker for earlier diagnosis and more effective therapies. Elevated LIF levels were significantly correlated with tumor cell status and response to chemotherapy.
Researchers at McMaster University have discovered a unique subset of cells, called human pluripotent founder cells, that appear to signal how surrounding cells will develop and grow. These 'kingpin' cells are found in primates but not in mice, suggesting they may play a key role in understanding cancerous tumours.
Researchers analyzed methods of targeted drug delivery to malignant tumors, exploring passive targeting, active targeting, and cell-mediated targeting. By understanding tumor structure and metabolism, scientists can develop personalized treatment approaches to increase efficiency and reduce side effects.
New research shows that magnetic hyperthermia therapy is tunable depending on nanoparticle diameter and material composition. The study demonstrates increased tumour absorption rates as particle diameter increases, offering new avenues for targeted cancer treatment.
A phase I clinical trial combining telomelysin and radiotherapy achieved an impressive 85% overall response rate (ORR) and complete tumor eradication in most patients. The therapy was safe and effective, even for elderly patients with health complications.
Scientists have found that successful removal of breast cancer tumors triggers a strong immune response, which clears disseminated tumor cells from lymph nodes and organs. In contrast, leaving behind primary tumor cells supports tumor growth and metastasis.
Breast cancer cells are inherently changeable, morphing from one cell type to another at the molecular level. This feature may promote resistance to certain therapies. The research provides new insights into how cancer cells develop and evolve within tumours.
Researchers found that tumor-associated macrophages release compounds that block the action of gemcitabine in malignant cells. The study suggests that patients with fewer macrophages in their tumors may respond better to chemotherapy. This discovery could lead to new approaches for treatment.
The study shows that Wt1 gene deletion causes deterioration of the pancreas and activates stellate cells, which play a key role in pancreatic cancer progression. The results suggest Wt1 gene is necessary for normal pancreas maintenance and repair after damage.
University of Otago scientists have developed a method to analyze the diversity of immune cells within bowel cancer tumours. This breakthrough could lead to more targeted treatments and improved patient outcomes.
A new study suggests that consuming thermally abused cooking oil may trigger genetic changes that promote the progression of late-stage breast cancer. Mice fed thermally abused oil developed more tumors and aggressive growth than those fed fresh soybean oil, highlighting a potential link between diet and cancer recurrence.
A research team has assembled a detailed atlas of bone marrow cells from AML patients, revealing six stages of white blood cell development and a role for differentiated tumor cells in suppressing immune responses. The study may lead to personalized therapies targeting specific AML cell types.
A team of researchers has created a detailed 'atlas' of cell states for acute myeloid leukemia (AML), a type of aggressive cancer. The atlas, generated using single-cell genomics and machine learning, identifies distinct cell types and their genetic characteristics, shedding light on the disease's heterogeneity.
Researchers develop a new assay to measure the eco-evolutionary interactions between sensitive and resistant tumor cells in non-small cell lung cancer. The study finds that by applying drug or eliminating fibroblasts, it is possible to 'treat the game', allowing for coopting of evolution to help patients
Researchers at the University of California San Diego discovered that breast tissue stiffening triggers multiple pathways to promote cancer cell formation. The study, published in PNAS, found that a subpopulation of mammary cells do not respond to stiffening, potentially leading to fewer or smaller primary tumors.
A new study has identified a pair of genes that can mimic the effects of BRCA proteins, potentially making tumor cells susceptible to PARP inhibitors. The researchers found that targeting these genes could improve treatment options for people with breast or ovarian cancer caused by BRCA defects.
Researchers discovered that STAT5B facilitates leukemogenesis in B-cell acute lymphocytic leukemia. They found that the absence of STAT5B increases interferon response and suppresses transformation. This understanding may enable precision medicine strategies to treat disease.
CKAP4, a plasma membrane protein, is released from pancreatic cancer cells in exosomes, allowing for its detection in serum. Researchers developed anti-CKAP4 monoclonal antibodies that block tumor signaling and inhibit growth, providing a potential therapeutic intervention.
The foundation awarded grants to nine early-career scientists working on novel approaches to fighting cancer. The recipients will receive up to four years of funding to explore their projects, which include gene editing technology CRISPR and single cell sequencing techniques.
Researchers have engineered immune cells to target different types of pediatric solid tumors, including brain tumors, with promising results. The treatment uses a surface marker called B7-H3, which is expressed on most pediatric cancer cells, and has been shown to eradicate tumors in mice.
Researchers at the University of Basel have developed a novel differentiation therapy that converts breast cancer cells into fat cells, impeding the formation of metastases in mice. The therapy combines two active substances, Rosiglitazone and Trametinib, to suppress tumor growth and spread.
Researchers propose a new perspective on cancer origins, highlighting the importance of mutation sequence and cell type in tumor growth and response to therapy. This approach may lead to new avenues for cancer prevention and treatment.
Researchers have identified a unique actin filament nanoscaffold triggered by molecular signals, which expands our understanding of cell movement. The discovery could yield insights into cancer metastasis, wound healing, and other cell-motility-related conditions.
Researchers at Far Eastern Federal University propose using stem cell activation to target glioma tumors. The approach aims to bring cancerous stem cells into an active state, making them vulnerable to chemotherapy. This method has been approved for publishing and is considered promising despite its risks.
Researchers examined cancer metabolism using flux-balance analysis and found that the Warburg effect provides a growth advantage for tumors, while glutamine addiction does not. The study also sheds light on the relationship between healthy cells and tumor cells under the reverse Warburg effect.
Researchers investigated nanomaterials' potential to activate the body's antitumor immune response. The study found that biomaterials can induce immunogenic cell death, leading to a decrease in metastases and an increase in long-term survival rates.
Researchers have identified a molecular mechanism that allows tumor cells to eliminate their neighbors through mechanical competition. The study found that compressed cells are killed by modulated EGFR/ERK signal, which is decreased and then leads to cell death. This discovery suggests a potential therapeutic strategy to halt tumor growth
Researchers at CCNY and Yale developed a new efficient computational model to simulate the behavior of soft, shape-changing cells. The model provides accurate capture of particle deformation and allows easy adjustment of cell-cell interactions, enabling studies on tumor growth and embryonic development.
Researchers at Osaka University have developed an AI-based system that can automatically differentiate between various types of cancer cells using microscopic images. The system achieved higher accuracy than human judgment, making it a potential game-changer in cancer diagnosis and treatment.
A new combined action drug was developed by Russian scientists using ionizing radiation and bacterial toxin, showing a 2,200 times stronger effect than separate use. The drug selectively targets tumor cells and facilitates visualization of tumors, making it a diagnostic tool for cancer treatment.
Researchers at Lund University identified three types of connective tissue cells that affect breast cancer development and metastasis. Patients with vascular fibroblasts or matrix fibroblasts in their tumours have a worse prognosis.
Researchers identified genetic changes that enable tumor cells to evade immune detection after stem cell transplant. Telomere length is linked to risk of death from high-dose chemotherapy in MDS patients.
Researchers used single-cell RNA sequencing to study gene expression in individual cells and identify unique therapeutic targets for cancers that form in specific cell types. The study found that mutations in certain genes can make cells vulnerable to apoptosis, providing a potential way to prevent or treat cancer.
Researchers at Max Delbrück Center develop strategy to selectively make cancer cells aggressive, making them vulnerable to anti-inflammatory substance. This approach aims to overcome chemotherapy resistance in certain types of cancer, such as non-small cell lung cancer.
A study published in Cell Reports identified an enzyme on the surface of some lung cancer cells that helps feed the cancer, making it a promising treatment target. The enzyme, TMPRSS11B, promotes tumor growth by encouraging lactate export and may be susceptible to antibody or small molecule therapy.
Scientists visualize immune system's action on tumor development, revealing its impact on cancer cell heterogeneity. The study highlights the potential for optimizing therapeutic combinations and sequences to improve immunotherapy outcomes.
Researchers have developed a new method to identify differences between single cells using single nucleotide variants, which can eliminate biases in traditional sequencing methods. This technique uses variant information to retrieve gene expression data, enabling better identification of tumor subpopulations.
Researchers identified TP63 as the culprit behind aggressive pancreatic cancer's addictive behavior. Suppressing its activity could lead to a tumor's demise. The study aims to understand why TP63 gets active in some patients' pancreas, with the goal of developing a treatment to improve their survival.
Researchers at Johns Hopkins Medicine have found a link between low levels of specific microRNA molecules and the development of pediatric brain tumors. Increasing these molecules may potentially treat low-grade gliomas, which affect mostly school-age children and young adults.
Researchers developed a gene analysis approach to spot immune cells in tumors, which could help doctors choose best treatments and predict therapy responses. This new method, called ImSig, provides a detailed picture of tumors and will aid scientists in studying the impact of immune cell types on cancer growth.
Scientists have developed novel conjugates made from antibodies and a kinesin spindle protein inhibitor, showing high effectiveness in vitro and tumor models. The linker between components allows for tuning the activity of the cytostatic drug, reducing side effects in cancer treatment.
Biologists at UC San Diego have discovered a human gene that inhibits HIV and makes tumor cells sensitive to DNA-damaging agents. The researchers found that the Schlafen 11 protein blocks the synthesis of viral proteins, allowing tumor cells to survive.
Researchers have used high-resolution electron microscopy to reveal how an anti-cancer virus interacts with tumor cells, increasing its potential. The Seneca Valley Virus selectively targets a receptor found in over 60% of human cancers, offering a promising approach for cancer treatment.
Researchers at Cold Spring Harbor Laboratory have identified molecular signals that can convert tumor-promoting fibroblasts into beneficial ones in pancreatic tumors. By manipulating these signals, they aim to recruit tumor-restricting cells into the anticancer fight and develop a combination therapy approach.
Researchers at VIB and Ghent University have discovered a novel method to block immunosuppression in cancer by targeting the protein assembly that dampens immune responses. This breakthrough could lead to the development of new therapies to stimulate immunity against tumor cells.
A study found that cancer stem cells with MHC Class I molecules upregulate and retain CDK1 protein, allowing them to initiate tumor growth. Sox2 transcription factor plays a key role in maintaining their stemness.
Researchers are using pulsed electric fields to treat tumors, inducing cell death and stimulating the immune system. The technology delivers genes encoding cancer-fighting proteins into tumor cells, increases drug efficiency, and affects cell signaling.
A study published in Nature identified a tumor cell population responsible for resistance to therapy and tumor relapse in basal cell carcinoma. The researchers found that vismodegib promotes the differentiation of tumor cells, leading to their elimination, but also reveals a dormant population of tumor cells with active Wnt signaling.
Researchers have developed a novel T cell bispecific antibody that guides immune cells to HER2-positive breast cancer cells, offering a targeted and safe approach. The therapy has shown promise in tackling certain breast cancers by exclusively targeting cancerous cells.
A specific protein called TEAD1 has been identified as a key regulator of tumor migration in glioblastoma, a devastating form of brain cancer. By deactivating this protein, researchers may be able to stop tumor cells from migrating away from the main tumor mass, increasing the success rate and overall survival time for patients.
Researchers developed switchable fluorescent proteins that can be controlled by green and orange light, enabling the study of dynamic processes in living cells without harming them. The proteins' efficient photoswitching allows for super-resolution fluorescence microscopy, a method previously hampered by toxic irradiation.